Attovia Therapeutics, Inc. (ATTO)

Attovia Therapeutics, Inc. is trading at $15.19, down 0.52% on the session. The 50 day average sits at $18.67 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 43.4, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $13.53 with resistance near $15.54, so that band frames the current range. Average daily movement is roughly $1.54, or about 10.1% of the share price, which is what any stop placement has to allow for. The overall health score of 34 out of 100 combines a trend score of 32, momentum of 44 and a risk score of 22.

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.